Show simple item record

dc.contributor.authorZubairi, I
dc.contributor.authorDean, Emma J
dc.contributor.authorMolife, L
dc.contributor.authorLopez, J
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorEl-Khouly, F
dc.contributor.authorSavulsky, C
dc.contributor.authorReyderman, L
dc.contributor.authorJia, Y
dc.contributor.authorHutton, E
dc.contributor.authorMorrison, R
dc.contributor.authorSweeting, L
dc.contributor.authorGreystoke, A
dc.contributor.authorBarriuso, J
dc.contributor.authorKristeleit, R
dc.contributor.authorEvans, T
dc.date.accessioned2016-12-16T15:41:04Z
dc.date.available2016-12-16T15:41:04Z
dc.date.issued2016
dc.identifier.citationPhase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors. 2016, 39: 206-206 Oncol Res Treaten
dc.identifier.urihttp://hdl.handle.net/10541/620052
dc.language.isoenen
dc.titlePhase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBeatson West of Scotland Cancer Centre, Glasgowen
dc.identifier.journalOncology Research and Treatmenten


This item appears in the following Collection(s)

Show simple item record